A Phase II, Open Label, Randomized Study of Osimertinib (TAgrisso) alone Versus Osimertinib plus Carboplatin/Pemetrexed for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose TUmours Harbour a T790M MutatIon Within the Epidermal Growth Factor Receptor Gene

Trial Profile

A Phase II, Open Label, Randomized Study of Osimertinib (TAgrisso) alone Versus Osimertinib plus Carboplatin/Pemetrexed for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose TUmours Harbour a T790M MutatIon Within the Epidermal Growth Factor Receptor Gene

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Carboplatin (Primary) ; Osimertinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TAKUMI Trial
  • Most Recent Events

    • 28 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 18 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top